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Abstract 19 
 20 
The aim of this work was to compare and contrast the mechanical properties and 21 
physical stabilities of oral films prepared with either thermal ink-jet printing (TIJP) or 22 
solvent casting (SC). Clonidine hydrochloride was selected as a model drug because 23 
of its low therapeutic dose and films were prepared using cellulose polymers. 24 
Mechanical testing showed that printed films had Young’s moduli and tensile strength 25 
values similar to the free film, while casted films were significantly more brittle. The 26 
drug also appeared to crystallise out of casted films during stress testing whereas 27 
printed films remained unchanged. The dissolution behaviour of printed and cast 28 
films were similar, because of the rapid disintegration of the polymer. The conclusion 29 
is that printing resulted in a better film than casting because the drug resided on the 30 
film, rather than in the film where it could exert a plasticising effect. 31 
 32 
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1. Introduction 38 
Oro-dispersible films (ODFs) have gained a lot of attention in recent years as a novel 39 
technology to overcome some of the common issues associated with conventional 40 
oral dosage forms, such as difficulty of swallowing (tablets and capsules) and stability 41 
(solutions and suspensions) (Banbury and MacGregor, 2011; Jeong et al., 2010; 42 
Saigal et al., 2008). ODFs are the size of a postage stamp and typically made from 43 
good film-forming polymers that dissolve or disintegrate rapidly upon contact with 44 
saliva (Banbury and MacGregor, 2011). They are flexible, which makes 45 
transportation and consumer handling much easier (Borsadia et al., 2003), and their 46 
manufacture can be cost effective (Reiner et al., 2010). 47 
 48 
ODFs are not, however, without drawbacks. One is their limited drug loading 49 
capacity, which makes them most suitable for highly potent, low-dose active 50 
pharmaceutical ingredients (APIs). Other limitations include the need for solvents and 51 
heat in the manufacturing process and the issue of taste masking. The main 52 
formulation challenge is to produce films with a rapid disintegration/dissolution time 53 
without compromising mechanical properties (Hoffmann et al., 2011).  54 
 55 
Well-established technologies such as solvent casting (SC) and hot-melt extrusion 56 
(HME) are used commercially to manufacture ODFs. In either case a polymer 57 
network is produced that is cut into strips of the required size. Both methods require 58 
the drug and the polymer to be mixed prior to forming the film. HME processing may 59 
not be suitable for APIs that are thermally labile or are degraded following shear 60 
stress (Janßen et al, 2013). One issue is that ODFs manufactured via these methods 61 
are essentially solid amorphous dispersions, with the API molecularly dispersed in 62 
the polymer matrix. It is well known that small molecular weight organic compounds 63 
typically exert a plasticising effect on polymers, which means the mechanical 64 
properties of the film may change depending on the amount and/or chemical 65 
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structure of the API incorporated. A further concern is that if the drug is formulated at 66 
a super-saturated concentration, relative to its solubility in the polymer, it is likely to 67 
phase separate by crystallising during storage. Crystallisation could potentially 68 
change the mechanical properties of the film, alter the dissolution rate, change the 69 
mouth feel and/or taste of the product and possibly alter the in-vivo fate of the drug 70 
(Cespi et al., 2011). 71 
 72 
An alternative route of manufacture is to cast a free film and then deposit the API 73 
onto it. One approach is to use flexography (a contact printing method that uses 74 
rotating rollers to deposit the printing solution onto the substrate). Genina et al (2012) 75 
used flexographic printing to formulate films for controlled release while Janßen et al 76 
(2013) used flexography to dispense rasagiline mesylate solution and tadalafil 77 
suspension onto hydroxypropylmethylcellulose films. Incorporation of 78 
hydroxypropylcellulose seemed to reduce drug crystallisation after printing. However, 79 
the main limitations of flexography are the risk of contamination, the relatively low 80 
resolution and the need to prepare a print roller, which means it is most suited to 81 
medium-scale production runs (Gonzalez-Macia et al., 2010).  82 
 83 
The API may also be deposited with thermal inkjet printing (TIJP). TIJP has the 84 
advantage of being able to deposit very small volumes (5-15 pL per droplet) with high 85 
precision. We have demonstrated before the deposition of low doses of salbutamol 86 
sulphate onto commercially available starch-based films with using conventional 87 
desktop printers (Buanz et al., 2011). TIJP technology has also been used to 88 
manufacture modified-release dosage forms by printing dots of solution onto a 89 
substrate (Scoutaris et al 2011, 2012) and it has been shown possible to fabricate 90 
three-dimensional particles by printing aqueous droplets into liquid nitrogen and 91 
subsequently freeze-drying (Mueannoom et al, 2012; Sharma et al, 2013). 92 
 93 
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Since TIJP deposits API solution onto a substrate, rather than dispersing API within a 94 
substrate, it seems reasonable to assume that printed films would maintain 95 
mechanical properties similar to that of the free film, and hence offer potential 96 
benefits compared with solvent casting for ensuring long-term stability. Testing this 97 
hypothesis is the specific aim of this work. Clonidine (CLN) was selected as a model 98 
drug. Clonidine is an antihypertensive drug that acts centrally by blocking α2-99 
adrenoreceptors. It also has sedative and analgesic effects (Ambrose et al., 2000). 100 
The drug is available as tablets of 100 and 300 µg as the chloride salt (Paediatric 101 
Formulary Committee, 2011) and the required dose to induce pre-operative sedation 102 
is 1- 5 µg/kg (Bergendahl et al., 2006). Such low doses make CLN an ideal candidate 103 
for formulation as oral films.     104 
 105 
2. Materials and methods 106 
2.1 Materials 107 
CLN, polyvinyl alcohol (PVA) 98% hydrolysed (Mw 13000-23000) and 108 
carboxymethylcellulose sodium salt medium viscosity (SCMC) were purchased from 109 
Sigma Aldrich (UK). Glycerol (analytical grade) was purchased from Fischer 110 
Scientific (UK). Bidistilled water (99.5%) was purchased from VWR International Ltd 111 
(UK), and methanol, absolute ethanol and acetonitrile (HPLC grade) were all 112 
purchased from Fischer Scientific (UK). Sodium 1-hexanesulphate (99%) was 113 
purchased from Acros organics (USA).  114 
 115 
2.2 Film preparation 116 
Films were prepared either by solvent casting or ink-jet printing. Concentrations were 117 
based on the minimum and maximum doses for sedation for children aged 6 months, 118 
5 and 14 years (Table 1). 119 
 120 
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2.2.1 Printed films 121 
The free film was composed of PVA and SCMC at 1:1 ratio with 24%w/v glycerol 122 
(Soutari et al, 2012). PVA (3.75g) was first dissolved in water (about 100mL) by 123 
heating to 80°C with continuous stirring. SCMC (3.75g) was then added and the 124 
solution was left to cool to room temperature with mixing, following which glycerol 125 
was added (36g) and the final volume was adjusted to150mL with water. The solution 126 
was poured into a non-stick baking tray (450cm2) and dried in an oven at 30°C. The 127 
resulting film sheets were used as substrates for printing.  128 
 129 
An HP printer (HP Deskjet 460, Hewlett-Packard Inc.) was used to print drug solution 130 
onto the film. Solutions of CLN (50mg/mL, prepared in 20% v/v methanol in water 131 
with 10%v/v glycerol) were printed from an HP 338 black cartridge. The cartridge was 132 
prepared by cutting off the top, removing the ink and rinsing with absolute ethanol. A 133 
2cm x 2cm black template was created in Word 2007 (Microsoft Inc., USA) and used 134 
to fire the cartridge. It was found that per print pass, 316.0 µg of CLN were deposited 135 
per strip (4cm2), equivalent to 79.0 µg/cm2. This value was then used to prepare CLN 136 
solutions suitable for printing films with doses equivalent to those given in Table 1. 137 
 138 
2.2.2 Casted films 139 
Appropriate volumes of CLN solutions (3.3, 1.18, 0.66, 0.5, 0.24 and 0.1 mg/mL to 140 
prepare 250, 90, 50, 38, 18 and 7.6 µg/strip, respectively) were added to a 141 
PVA:SCMC solution (prepared as above) to obtain the required dose. Solutions were 142 
left to stir for one hour and then were cast in a non-stick baking tray and dried at 143 
30°C. The resulting films were cut to the required size (4 cm2) and stored over silica 144 
gel in a desiccator until use. 145 
 146 
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2.3 Drug content analysis 147 
Films were dissolved in a solution of 20% methanol in water (4 cm² in 20 mL). 148 
Solutions were filtered through a 0.45 µm filter (Millex syringe-driven filter unit, 149 
Millipor Ltd, Ireland). The filtrate was analysed with high performance liquid 150 
chromatography (HPLC) equipped with a UV-diode-array detector (Agilent 151 
Technologies 1200 series, Germany). The mobile phase was a mixture of 0.1% v/v 152 
triflouroacetic acid in water and acetonitrile (80:20% v/v) delivered at a rate of 1.0 153 
mL/min. The stationary phase was a Phenomenex Synergy max C-12 column 154 
(250mm x 4.6mm x 4µm; Phenomenex Synergy max, USA) kept at 40°C and the 155 
injected sample volume was 10µL. Peaks were evaluated at 220nm. The percentage 156 
recovery calculated for solutions made with blank film sheets dissolved in the 157 
solutions spiked with known amount of CLN (in the range of 100 to 300 µg/mL, n=9) 158 
was 98.29 ± 1.82%. Limit of detection and limit of quantification were found to be 159 
0.15µg/mL and 0.68µg/mL, respectively. Method calibration was performed with a 160 
series of standard CLN solutions in 20% methanol in water. A linear response was 161 
seen between 0.25 and 100 µg/mL (r2 =0.9997). 162 
 163 
2.4 Characterisation of films 164 
2.4.1 X-Ray Powder Diffraction (XRPD)  165 
Powder diffraction data were collected with a PW3830 diffractometer (Philips, 166 
Netherlands) operated with Cu K-alpha radiation (λ = 1.540598 Å) at 45 kV and 30 167 
mA. Scanning was performed from 5° to 30° 2θ at 0.02° step size and 2.85 seconds 168 
per step. Xpert data viewer software (PANalytical B.V, Netherland) was used to 169 
analyse the data.  170 
 171 
2.4.2 Thermogravimetric analysis (TGA)  172 
Measurements were performed with a Pyris-6 TGA (PerkinElmer, UK). Samples were 173 
heated at 10°C/min using nitrogen as purge gas (20mL/min). Data collection and 174 
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analysis were performed using Pyris software (version 3.18). Mass loss (%w/w) 175 
and/or onset temperature were calculated and reported as mean ± SD. 176 
 177 
2.4.3 Fourier Transform Infrared (FTIR)  178 
FTIR spectra were collected with a PerkinElmer Spectrum 100 FTIR spectrometer in 179 
the range of 4000 to 650 cm-1 at ambient conditions. Spectra were analysed with 180 
Spectrum Express software (application version 1.02.00.0014, 2008). 181 
 182 
2.4.4 Tensile testing 183 
An Instron Universal Testing Instrument (Model 5567, Instron Ltd, Norwood, USA) 184 
was used to measure the mechanical properties of films (2cm x 2cm) at a rate of 185 
10mm/min and 100N static load (2kg). The cut-off point was when the film was 186 
completely separated into two pieces. The tensile strength and Young’s modulus 187 
were measured. Data were analysed using Bluehill software 2 (version 2.6). 188 
 189 
2.4.5 Dynamic Mechanical Analysis (DMA) 190 
A Q800 Dynamic Mechanical Analyser (TA instruments, Waters LLC) was used to 191 
measure the mechanical properties of the films. Advantage software for Q series 192 
version 2.8.0.394 was used to collect the data and TA Universal Analysis software 193 
(V4. 7A TA 2000) to analyse the data. Samples were held in a film tension clamp. 194 
Experimental parameters were amplitude, 15-20um; preforce load, 0.01N; force 195 
track, 125%; frequency, 10Hz. Experiments were performed at 3°C/min from room 196 
temperature to 200°C.  197 
 198 
2.4.6 Polarised light microscopy (PLM) 199 
A Nikon microphot-FXA light microscope was used to collect optical images with an 200 
Infinity 2 digital camera and capture application software (version 3.7.5).  201 
 202 
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2.4.7 Dynamic Vapour Sorption (DVS) 203 
Films were placed in a glass pan for Dynamic Vapour Sorption (DVS-1) (Surface 204 
Measurement Systems, London, UK) at 30°C and kept at 0% RH for 90 minutes. 205 
Relative humidity was then scanned from 0 to 95% with intervals of 5% RH over 10 206 
minutes. The change of sample weight due to water uptake or loss was recorded 207 
gravimetrically with the ultra-microbalance. The relative humidity (RH) around the 208 
sample was controlled by mixing saturated and dry carrier gases (Nitrogen) with 209 
electronic mass flow controllers. 210 
 211 
2.4.8 Thickness and disintegration 212 
Thickness of films (2cm x 2cm) was measured using a digital micrometer at five 213 
points of each sample, at the four corners and the centre in triplicate, and reported as 214 
mean ± SD. 215 
 216 
The disintegration test described by Zhao et al (2009) for capsule and tablet coatings 217 
was modified to suit oral films. A device was constructed to hold the film between two 218 
clamps and a weight of 725mg was placed on top of the film. The disintegration 219 
medium used was 15 mL (37 ± 1 °C) of a simulated saliva solution (Peh and Wong, 220 
1999) containing Na2HPO4 (2.38 g), KH2PO4 (0.19 g) and NaCl (8 g) in distilled water 221 
(1 L). The pH of the solution was adjusted to 6.75 with phosphoric acid. The time 222 
taken for the film to break was measured by filming with a black and white CCD 223 
camera (model ART-CAM-130MI-VM). Images were analysed with FTA 32 software 224 
(Version 2.0, First Ten Angstroms Inc, USA). The disintegration time was calculated 225 
as the time between adding the disintegration medium and visual observation of the 226 
film breaking (n = 3).  227 
 228 
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2.4.9 In vitro drug release  229 
Dissolution tests were conducted in a water-jacketed glass vessel (outer and inner 230 
diameters of 8 and 6 cm, respectively and 150mL capacity). Films were placed on a 231 
plastic sieve of 3cm in diameter and 40 mL of simulated saliva solution was used as 232 
a dissolution medium. A PTFE magnetic stirrer was used for agitation (size of 10cm x 233 
6cm) and the temperature was maintained at 37 ± 1 °C with the help of a 234 
refrigerating/heating circulator with programmable digital temperature controller 235 
(Polyscience, Division of Preston Industries, Inc., USA). Samples of 1mL were 236 
collected at time intervals of 0.5, 1, 2, 4, 8, 12, 16 and 30 min and replaced with a 237 
fresh medium kept at ~ 37 °C. Samples were then filtered through 0.45 µm filters and 238 
analysed with HPLC in accordance with the method above. 239 
    240 
2.5 Statistical analysis 241 
Results were analysed and compared with Student t-test (α=0.05) using Origin® 8.6 242 
software (OriginLab Corporation, USA). 243 
 244 
3. Results and discussion 245 
 246 
3.1 Drug content and dose uniformity 247 
The amount of CLN deposited by printing showed a linear correlation with the drug 248 
feed solution concentration as shown in Figure 1 (r2 = 0.9997). This is consistent with 249 
the salbutamol sulphate (SS) data reported in an earlier study (Buanz et al, 2011). 250 
Films prepared by blending CLN with the polymer and casting had a lower drug 251 
content than films prepared by printing (Table 2). The variation of dose was higher 252 
with solvent casting method (CV= 10.8 ± 6.0%) compared with printing (CV= 2.5 ± 253 
2.2%). The higher dose variability in casted films may be a result of inhomogeneity in 254 
blending or variability in film thickness, but the results immediately indicate the 255 
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potential utility of ink-jet printing for preparing low dose and narrow therapeutic index 256 
medicines. 257 
 258 
3.2 Characterisation of films 259 
In general, pharmaceutical polymer films should have good flexibility, elasticity and 260 
softness but possess enough strength to withstand mechanical stresses during 261 
manufacturing and dispensing (Preis et al., 2013; Prodduturi et al., 2004). Hydrophilic 262 
polymers are commonly used in pharmaceutical oral dosage forms (Prodduturi et al., 263 
2004), which generally means that exposure to humidity during storage and use can 264 
affect their properties (Gontard and Ring, 1996). Here, mechanical testing and 265 
polarised-light microscopy were used to characterise the films after manufacture and 266 
following exposure to elevated humidity. 267 
 268 
3.2.1 Tensile test 269 
Tensile stress at the break point and Young’s modulus were calculated for drug-270 
loaded films (Table 3). Films prepared by SC had higher tensile stress values, which 271 
indicates that the films were harder than those made by TIJP (Garsuch and 272 
Breitkreutz, 2010). Skulason et al (2009) reported that Carpabol films prepared by 273 
SC have high tensile strength and low elasticity. In general, higher Young’s modulus 274 
values for films made by SC also reflect their increased brittleness (Biliaderis et al., 275 
1999). 276 
 277 
Residual water in films can affect their mechanical properties and lead to increased 278 
elasticity by its plasticizing effect (Karisson and Singh, 1998) and thus any variation 279 
in water content between films prepared by TIJP and SC could be the reason for the 280 
difference in their mechanical properties. However, as shown by values of water 281 
content given in Table 3, the difference was not significant (p > 0.05). This suggests 282 
that location of drug within the films is in fact the critical factor.  283 
 12 
 284 
3.2.2 Glass transition measurement 285 
XRPD patterns shown in Figure 2 confirm the amorphous nature of the free and 286 
drug-loaded films. The glass transition temperature (Tg) of a polymer is one of the 287 
important parameters that reflects its mechanical properties with temperature and is 288 
associated with a small change in the heat capacity of the system due to the strong 289 
glass forming properties of polymers (Fadda et al., 2010). There is no single 290 
temperature at which Tg occurs; rather, the value depends on the technique and 291 
experimental parameters used to measure it.  292 
 293 
DMA was used to measure the glass transition temperatures of the films. Tg is 294 
usually defined as a peak in the tan delta signal (the ratio of the storage to loss 295 
moduli) or the inflection point of the decrease in storage modulus (Gontard and Ring, 296 
1996). Here, it was not possible to use either point. The storage modulus data are 297 
shown in Figure 3. It is apparent that there is an increase in storage modulus after 298 
100 oC. This is because the films lost water during heating and so became very 299 
brittle. Similarly, there was no peak in the tan delta signal (data not shown) because 300 
the polymers thermally degraded. This highlights one significant problem when using 301 
thermal methods at slow heating rates. The increase in temperature acts to dry the 302 
sample and since water is often a plasticiser the mechanical properties of the film 303 
change during measurement. Hence, it was not possible to determine the Tg values 304 
of the films.  305 
 306 
FTIR data, however, did show evidence of CLN-polymer interactions at room 307 
temperature (Table 4). Shifts are noticeable in the bands at 3274.8 (broad), 2941.6 308 
and 1380.5 (from the free film) in the drug-loaded films, which can be assigned to 309 
hydroxyl (OH) stretch, and carbon-hydrogen (C-H) stretch and C-H bend, 310 
respectively (Coates, 2000), suggesting that the drug interacts with PVA but not with 311 
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SCMC, possibly through hydrogen bond with the PVA OH group. Larger shifts from 312 
the free film values are seen in the case of SC samples, indicating the drug is more 313 
dispersed in the polymer matrix than in the printed films. It is noticeable that the main 314 
bands characteristic for CLN, such as the secondary amine N-H stretch, bend and 315 
aliphatic secondary amine C-N stretch (at 3330, 1649 and 1338) are not seen, which 316 
could be because they are masked by peaks from the polymers or because the drug 317 
concentration is very low. 318 
 319 
3.2.3 Critical humidity measurement 320 
The critical humidity (cRH) is the humidity at a particular temperature that will cause 321 
a phase transition (such as glass transition). Its determination is important along with 322 
the threshold temperature in order to define the storage conditions required to 323 
prevent phase changes during processing and storage (Burnett et al., 2004). 324 
 325 
DVS is commonly used to determine cRH. cRH is usually taken to be the RH where a 326 
reduction in mass is seen, corresponding to expulsion of absorbed water as the 327 
sample crystallises. For CLN films the sample weight continued to increase with a 328 
increasing of RH (Figure 4), and so it was not possible to determine a cRH value. 329 
Presumably, this is because the majority of the sample is polymer. The method of 330 
preparation (TIJP or SC) did not seem to have an effect on water sorption at lower 331 
humidity as the changes of weight with time (and humidity) of both samples appear to 332 
be superimposed. However, at higher humidity a higher weight increase is observed 333 
for printed films. Possible reasons for this difference are discussed below. 334 
 335 
3.2.4 Physical stability 336 
Stability here refers to physical form rather than chemical degradation. Upon 337 
exposure to increased temperature and/or humidity the films may absorb water and 338 
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be plasticised thus increasing the rate of molecular mobility of dispersed drug 339 
molecules and potentially causing phase separation by crystallisation.  340 
 341 
Films containing the highest doses of CLN (90 and 250 µg/strip) were subjected to 342 
high temperature and humidity (60°C and 75 %RH) in the DMA for about 13 hours. 343 
The DMA signal (storage modulus) did not change after initial equilibration to the test 344 
parameters. This indicates that there was no significant change in the mechanical 345 
properties of the films over the test period. However, PLM images (Figure 5) showed 346 
clear signs of crystallisation in the 250 µg/strip prepared by SC. No such 347 
crystallisation was observed for the lower dose film prepared by SC or films prepared 348 
by TIJP.  349 
 350 
In addition, the films used during the DVS and DMA experiments were also checked 351 
with PLM (Figure 6). These films were exposed to relative humidity from 0 to 90% RH 352 
at 30°C. No signs of crystallisation can be seen in films tested with DMA but clear 353 
crystallisation is evident in the 250 µg/strip films prepared by SC tested with DVS and 354 
the beginning of crystal growth is seen in the 90 µg/strip films. Drug in films prepared 355 
by TIJP showed no evidence of crystallisation.  356 
  357 
3.2.1 Disintegration and drug release 358 
Typical disintegration times for ODFs range from 5 to 30 s (Banhart, 2008). There 359 
have been several attempts to mimic in vivo conditions, particularly the low volume of 360 
saliva, such as the slide frame method and the Petri dish method (Garsuch and 361 
Breitkreutz, 2010; Hoffmann et al., 2011). Measurement of the contact angle with 362 
time as a drop of water is placed on a film has also been used to assess 363 
disintegration (Garsuch and Breitkreutz, 2009). The lack of official tests makes the 364 
comparison between various published results a challenging task.  365 
 366 
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Here, the images for film disintegration were captured with the help of a CCD 367 
camera, allowing precise time measurement. For the dissolution test a volume of 40 368 
mL was the lowest that allowed the film (placed on the plastic mesh) to float freely 369 
while the medium was mixed. The results of both tests are described below.  370 
 371 
The results from the disintegration test show that the time taken for the samples to 372 
disintegrate is in the range of 20 to 60 s (the time recommended by the FDA is 30 s, 373 
Centre for Drug Evaluation and Research, 2008). This means that some samples 374 
exceeded the recommended limit. The main factor for that would be the thickness as 375 
it is a key factor in determining the disintegration time (Garsuch and Breitkreutz, 376 
2010). 377 
 378 
Figure 7 shows the release profiles of films containing 250 µg/strip of CLN prepared 379 
by either TIJP or casting (SC) in simulated saliva fluid. It is noticeable that both 380 
samples achieved more than 50 (t50%) and 80% (t80%) of drug release within 8 and 30 381 
min, respectively. To compare the release profiles of films prepared by TIJP with 382 
films prepared by SC, difference (f1) and similarity (f2) factors were calculated from 383 
equations 1 and 2 (n = 3). f2 can have a value of 0 to 100 where 100 means the 384 
profile of the tested product is the same as that of the reference and 0 means they 385 
are completely different (Costa and Sousa Lobo, 2001). The FDA adopted both 386 
factors as a way to assess the similarity of in vitro dissolution profiles where a value 387 
of 0 to 15 for (f1) and 50 to 100 for (f2) indicate the two profiles to be similar (Center 388 
for Drug Evaluation and Research, 1997).  f1 and f2 for films containing 250 µg/strip 389 
prepared by TIJP were calculated to be 1.25 and 64.7, respectively, which means 390 
that the release profile of TIJP films is similar to that of films prepared by SC. 391 
     392 𝒇𝟏 =    𝑹𝒕 −   𝑻𝒕𝒏𝒕!𝟏   ∕    𝑹𝒕𝒏𝒕!𝟏   ×  𝟏𝟎𝟎               Equation 3.1   393 
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𝒇𝟐 = 𝟓𝟎  𝒍𝒐𝒈 𝟏 +    𝟏𝒏 𝑹𝒕 − 𝑻𝒕 𝟐𝒏𝒕!𝟏 !𝟎.𝟓 ×  𝟏𝟎𝟎   Equation 3.2 394 
 395 
Where n is the number of data points and R and T are the cumulative release 396 
percentages for the reference (SC) and the test (TIJP) films at time t.   397 
The release kinetics of CLN from the films were examined with four mathematical 398 
release models; zero-order, first-order, Higuchi and Hixson-Crowell models 399 
(Equations 3 to 6) (Costa and Sousa Lobo, 2001). Where 𝑄! and 𝑄! are the amount 400 
released after time t and initial amount of the drug, respectively while k is the release 401 
constant. 402 
 403 𝑸𝒕 = 𝑸𝟎   +   𝑲𝒕      Equation 3 404 𝐥𝐧𝑸𝒕   =    𝐥𝐧𝑸𝟎   + 𝑲𝒕      Equation 4 405 𝑸𝒕   = 𝑲 𝒕       Equation 5 406 𝑸𝒕⅓   =   𝑸𝟎⅓ + 𝑲𝒕      Equation 6 407 
 408 
The correlation coefficients (r2) for films prepared by TIJP or SC are given in (Table 409 
5). The highest r2 value was for Hixson-Crowell model. This suggests that drug 410 
release from both samples followed this model, which indicates drug release by 411 
erosion (Costa et al., 2003). This could be a result of incorporating SCMC in the 412 
formulation (Dabbagh et al., 1999; Hussain et al., 1994). This could be related to the 413 
presence of ionisable carboxylic acid group in SCMC, which increases the dissolution 414 
of the polymer (Hussain et al., 1994). Dabbagh et al (1999) noticed a decrease in 415 
matric erosion when propranolol hydrochloride was added, which they suggested to 416 
be a result of an interaction between the drug and the polymer. In this work the FTIR 417 
data presented earlier suggest that clonidine hydrochloride interacts with PVA and 418 
not SCMC in the tested films. This supports the suggestion that the carboxylic acid 419 
groups of SCMC are available for ionisation and thus allows the polymer erosion. 420 
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Hussain et al (1994) also reported that when comparing the erosion rate of SCMC 421 
matrices containing either a drug that interacts with the polymer or not, a faster rate 422 
is observed when no interaction is present.  423 
 424 
4. Conclusion 425 
The results indicate that films prepared by printing are significantly different in terms 426 
of mechanical properties and stability compared with films prepared by casting. In 427 
particular, the properties of the printed films are much more similar to those of the 428 
free film. It seems likely that the process of solvent casting results in a molecular 429 
dispersion of CLN throughout the polymer, analogous to a solid-amorphous 430 
dispersion. FTIR data confirm chemical interaction between the drug and the 431 
polymer. The drug appears to exert an anti-plasticising effect, increasing the 432 
brittleness of the film. When stored at elevated temperature and humidity the drug is 433 
seen to phase separate, resulting in crystal formation. 434 
 435 
The exact nature of the printed film is harder to elucidate from the data. It is clear that 436 
immediately after printing the drug will be present in solution as droplets on the 437 
surface of the polymer film. Previous experience with printing drug solutions (Buanz 438 
et al, 2013) has shown us that the small droplets evaporate very quickly, resulting in 439 
formation of small (<5 µm) crystals. Thus, a reasonable hypothesis would be that in 440 
the printed films the drug exists either on the surface or in the top layer of the film as 441 
small crystallites. The drug is thus not acting as an anti-plasticiser and so the 442 
mechanical properties of the printed film remain similar to those of the free film. The 443 
printed film appears amorphous by XRPD because the drug content is low and small 444 
crystals do not diffract sufficiently to appear in the pattern. Upon storage at elevated 445 
temperature and humidity the printed film remains stable because it has already 446 
phase separated. Again, it is likely that the small size of any crystallites mean they 447 
were not visible with PLM. 448 
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 449 
Janßen et al (2013) did not observe any effect on the mechanical properties of films 450 
upon printing drug solutions using flexographic printing. They argue that in 451 
manufacturing oral films by this method the properties of the plain films can be 452 
assessed and it would not be necessary to evaluate the medicated films, which they 453 
envisage to add flexibility to the manufacturing process. Our work indicates a similar 454 
conclusion can be drawn in regard to ink-jet printing.  455 
 456 
  457 
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 568 
Age/Body weight 
Target dose 
(µg/strip) 
Required feed 
solution conc. 
(mg/mL) 
6 months/7.6Kg 
7.6 1.20 
38 2.85 
5 year-old/18Kg 
18 6.01 
90 7.91 
14-year old/ 
50Kg 
50 14.23 
250 39.54 
 569 
Table 1. Clonidine hydrochloride doses and the required solution 570 
concentrations used for depositing the drug by TIJP. 571 
  572 
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 573 
Table 2. A comparison between drug content in films prepared by SC and TIJP 574 
methods. 575 
  576 
Target 
conc. 
(µg/strip) 
Calculated Concentration (µg/strip) 
SC (weight-based) SC (area-based) TIJP (area-based) 
Mean ± 
SD 
% Difference 
Mean ± 
SD 
% Difference 
Mean ± 
SD 
% 
Difference 
7.6 9.9 ± 1.3 30.1 ± 17.4 10.6 ± 0.5 39.1 ± 6.5 12.2 ± 0.4 60 ± 5.0 
18 26.0 ± 2.6 44.3 ± 14.3 18.6 ± 1.0 3.5 ± 5.8 19.1 ± 1.1 5.9 ± 5.9 
38 
31.1 ± 
15.0 
-18.3 ± 39.5 30.3 ± 6.5 -20.3 ± 17 36.5 ± 1.7 -4 ± 4.4 
50 51.8 ± 2.3 3.6 ± 4.5 42.7 ± 4.3 -14.7 ± 8.5 45.9 ± 0.1 -8.1 ± 0.3 
90 
116.7 ± 
43.5 
29.4 ± 48.3 73.5 ± 8.4 -18.3 ± 9.3 80.4 ± 0.4 -10.7 ± 0.4 
250 
226.7 ± 
5.8 
-9.3 ± 2.3 
203.9 ± 
23.9 
-18.4 ± 9.6 
252.8 ± 
2.5 
1.1 ± 1 
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 577 
Sample 
Free film 250 µg/strip 
SC TIJP 
Tensile stress (MPa) 19.3 ± 2.9 41.9 ± 1.9 25.2 ± 1.1 
Young's modulus (MPa) 547.8 ± 54.2 1423.8 ± 259.1 658.2 ± 127.6 
Water content (%w/w) 8.9 ± 0.1 5.8 ± 0.3 6.6 ± 1.1 
Thickness (mm) 0.1 ± 0.02 0.1 ± 0.01 0.1 ± 0.01 
Disintegration time (seconds) NA 23.3 ± 5.6 30.5 ± 4.6 
 578 
Table 3. Mechanical properties, water content, thickness and disintegration 579 
times for films prepared by SC or TIJP methods. 580 
 581 
  582 
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 583 
Sample 
TIJP 250 
µg/strip 
SC 250 
µg/strip 
Free film 
PVA 
powder 
SCMC 
powder 
CLN 
powder 
Wavelength 
(cm-1) 
 
 
3276.4 3270.8 3274.8 3278.7 3266.8 3330.8 
2938.0 2922.4 2941.6 2942.6 NA 3082.5 
2915.8 2913.6 2917.9 2907.7 2902.7 3041.7 
1594.8 1594.5 1593.6 1417.2 1589.4 2987.1 
1415.2 1414.8 1415.3 1420.0 1413.7 2950.0 
1378.7 1375.9 1380.5 1377.8 NA 2800.0 
1321.6 1321.5 1322.0 1323.7 1324.1 2741.2 
1092.3 1091.0 1092.3 1141.8 NA 1649.3 
1037.7 1036.1 1038.5 1088.3 1037.3 1606.4 
919.7 919.3 919.7 917.0 NA 1581.1 
848.2 847.3 847.1 833.4 NA 1445.5 
NA NA NA NA NA 1435.3 
NA NA NA NA NA 1494.0 
NA NA NA NA NA 1337.6 
 584 
Table 4. Main FTIR transmittance peaks of drug-free films and films containing 585 
250 µg/strip prepared by SC or TIJP. 586 
  587 
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 588 
Table 5. Regression values for the dissolution profiles for 250 µg/strip CLN 589 
films (r2 is the correlation coefficient, a is the intercept and b is the slope). 590 
 591 
 592 
 593 
  594 
Sample 
SC TIJP 
r2 b a r2 b a 
Zero-
order 
0.891 2.2 26.7 0.881 2.2 26.7 
1st order 0.747 0.05 3.3 0.685 0.05 3.3 
Higuchi 0.988 14.4 9.6 0.983 14.0 10.0 
Hixson-
Crowell 
0.997 29.7 6.8 0.996 29.0 6.2 
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 595 
Figure 1. Amount of clonidine hydrochloride deposited as a function of feed 596 
solution concentration (some error bars are too small to appear on the graph) 597 
  598 
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 599 
 600 
Figure 2. XRPD patterns of medicated films prepared by SC or TIJP in 601 
comparison to CLN raw material and the free film. 602 
  603 
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 604 
Figure 3. Storage modulus as a function of temperature for drug-free films and 605 
films containing 250µg/strip prepared by SC or TIJP methods. 606 
  607 
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 608 
Figure 4. DVS results of relative humidity (RH) scan for films containing 250 609 
µg/strip prepared by SC or TIJP methods.   610 
  611 
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 613 
 614 
Figure 5. PLM images of films after being tested with isothermal constant 615 
humidity experiments (60°C and 75% RH) in the DMA. 616 
 617 
 618 
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  620 
Figure 6. PLM images of films subjected to RH scan at 30°C in (left) DVS and 621 
(right) DMA. 622 
 623 
  624 
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 625 
Figure 7. Dissolution profiles for films containing 250 µg/strip CLN prepared by 626 
SC or TIJP methods (n = 3). 627 
  628 
 629 
